Genmab Share Price Nasdaq Copenhagen
Stocks
DK0010272202
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 11TCr 1.75TCr 1.53TCr 1.42TCr 1.31TCr 2.48TCr 1,67300Cr 2.52TCr 17TCr 6.64TCr 82TCr 6.59TCr 6.44TCr 2,83400Cr | P/E 2026 * |
24.5x | P/E 2027 * | 17x |
|---|---|---|---|---|---|
| Enterprise Value | 13TCr 2.05TCr 1.79TCr 1.65TCr 1.53TCr 2.9TCr 1,95500Cr 2.95TCr 20TCr 7.76TCr 96TCr 7.69TCr 7.53TCr 3,31000Cr | EV / Sales 2026 * |
4.79x | EV / Sales 2027 * | 3.85x |
| Free-Float |
95.41% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Genmab
| 1 day | -0.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/06/2010 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 01/03/2020 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 16/08/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 01/11/2003 | |
| Director/Board Member | 58 | 01/01/2015 | |
| Director/Board Member | 75 | 01/01/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.33% | +4.14% | - | - | 1.75TCr | |
| +1.84% | -0.66% | +59.82% | +92.96% | 5.49TCr | |
| -4.14% | -8.06% | +58.96% | +118.67% | 5.46TCr | |
| -2.24% | +3.59% | +17.75% | +477.47% | 2.51TCr | |
| -1.60% | -6.21% | -18.96% | -15.21% | 2.31TCr | |
| +2.43% | +1.06% | +42.44% | -1.27% | 1.99TCr | |
| -6.84% | +2.18% | +195.12% | +357.18% | 1.65TCr | |
| +8.74% | +3.51% | +51.91% | +726.40% | 1.57TCr | |
| -1.05% | +1.16% | +25.95% | +194.27% | 1.42TCr | |
| -4.16% | +1.63% | +70.13% | +142.72% | 1.24TCr | |
| Average | -0.74% | -0.10% | +55.90% | +232.58% | 2.63TCr | |
| Weighted average by Cap. | -0.86% | -1.40% | +53.42% | +190.48% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.8TCr 428.06Cr 374.42Cr 345.36Cr 318.97Cr 605.24Cr 41TCr 615.42Cr 4.13TCr 1.62TCr 20TCr 1.61TCr 1.57TCr 69TCr | 3.28TCr 501.96Cr 439.06Cr 404.98Cr 374.04Cr 709.73Cr 48TCr 721.67Cr 4.84TCr 1.9TCr 24TCr 1.88TCr 1.84TCr 81TCr |
| Net income | 473.77Cr 72Cr 63Cr 58Cr 54Cr 102.46Cr 6.91TCr 104.18Cr 698.55Cr 274.32Cr 3.4TCr 272.08Cr 266.16Cr 12TCr | 707.38Cr 108.2Cr 95Cr 87Cr 81Cr 152.98Cr 10TCr 155.55Cr 1.04TCr 409.59Cr 5.08TCr 406.24Cr 397.4Cr 17TCr |
| Net Debt | 1.93TCr 294.78Cr 257.85Cr 237.83Cr 219.66Cr 416.8Cr 28TCr 423.81Cr 2.84TCr 1.12TCr 14TCr 1.11TCr 1.08TCr 48TCr | 1.18TCr 179.87Cr 157.33Cr 145.12Cr 134.03Cr 254.32Cr 17TCr 258.59Cr 1.73TCr 680.9Cr 8.45TCr 675.35Cr 660.65Cr 29TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
